Post

New research · Urology
The Lancet. Oncology · 4d
Cohort studyThe Lancet. Oncology · 2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi … Roger Li
Read paper
UrologyCohort study

Cretostimogene immunotherapy showed complete response in 75% of high-risk bladder cancer.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Mark D Tyson … Roger Li
The Lancet. Oncology · 2026
Background

There are few bladder-sparing treatment options for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer that are effective and have a manageable adverse event profile.

Methods

Received intravesical cretostimogene (1 × 10 12 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.

n = 165 patients
Results
75% [95% CI 66·3-83·2]
the cancer completely disappeared in three-quarters of patients
n = 165 patients
“
Conclusion · 1 of 2

Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events.

Conclusion · 2 of 2

Cretostimogene shows promise as an innovative bladder-sparing treatment for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Animal / Preclinical
less than 1.5 pixels
the tracking method was very accurate, with minimal error in position
Animal / Preclinical
43.5%
the magnetic resonance imaging signal brightness in cancerous areas was substantially higher
Study
(156.3±24.2) μmol/L
This Michaelis constant indicates the transporter's affinity for selenocystine.
AI / Informatics
0.787
this shows good accuracy in automatically drawing the rectal spacer's boundary
Review
41.6%
Share with new overactive bladder at 20 years
Animal / Preclinical
55.8%
Multidrug resistance found in more than half of cat urine bacteria, limiting treatment options.
Study
91%
Treatment plans agreed with the reference scan in 30 of 33 patients
Case-control
OR = 4.23
Higher triglycerides linked to higher odds of prostate cancer